<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2505233734
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEROZA 1 g powder for Solution for Injection or Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEROPENEM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        356.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DEMO S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DEMO S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Meroza contains the active substance meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections.</p><p>&nbsp;</p><p>Meroza is used to treat the following in adults and children aged 3 months and older:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection affecting the lungs (pneumonia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung and bronchial infections in patients suffering from cystic fibrosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated infections in the abdomen.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections that you can catch during or after the delivery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissues infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial infection of the brain (meningitis).</p><p>&nbsp;</p><p>Meroza may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>&nbsp;</p><p>Meroza may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Meroza</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to meropenem or any of the other ingredients of Meroza (listed in Section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins, or carbapenems as you may also be allergic to meropenem.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong><strong> </strong></p><p>Talk to your doctor, pharmacist or nurse before using Meroza:</p><p>●&nbsp;&nbsp;&nbsp; if you have health problems, such as liver or kidney problems.</p><p>●&nbsp;&nbsp;&nbsp; if you have had severe diarrhoea after taking other antibiotics.</p><p>You may develop a positive test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells. Your doctor will discuss this with you.</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or nurse before using Meroza.</p><p>&nbsp;</p><p><strong>Other medicines and </strong><strong>Meroza</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking or have recently taken or might take any other medicines. This is because Meroza can affect the way some medicines work and some medicines can have an effect on Meroza</p><p>&nbsp;</p><p>In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:&nbsp;</p><p>●&nbsp;&nbsp;&nbsp; Probenecid (used to treat gout).</p><p>●&nbsp;&nbsp;&nbsp; Valproic acid/sodium valproate/valpromide (used to treat epilepsy). Meroza should not be used because it may decrease the effect of sodium valproate.</p><p>●&nbsp;&nbsp;&nbsp; Oral anti-coagulant agent (used to treat or prevent blood clots).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy.</p><p>Your doctor will decide whether you should use Meroza.</p><p>&nbsp;</p><p>It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving meropenem. Small amounts of this medicine may pass into the breast milk. Therefore, your doctor will decide whether you should use Meroza while breast-feeding.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>No studies on the effect on the ability to drive and use machines have been performed.</p><p>Meropenem has been associated with headache and tingling or pricking skin (paraesthesia). Any of these side effects could affect your ability to drive or operate machines.</p><p>Meroza may cause involuntary muscle movements which may cause the person&#39;s body to shake rapidly and uncontrollably (convulsions). This is usually accompanied with a loss of consciousness. Do not drive or use machines if you experience this side effect.</p><p>&nbsp;</p><p><strong>Meroza contains sodium. </strong></p><p>&nbsp;</p><p>Meroza 500 mg: This medicine contains approximately 45 mg of sodium (main component of cooking/table salt) in each 500 mg dose. This is equivalent to 2.25 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>Meroza 1 g: This medicine contains approximately 90 mg of sodium (main component of cooking/table salt) in each 1.0 g dose. This is equivalent to 4.5 % of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>If you have a condition which requires you to monitor your sodium intake, please inform your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>Use in adults</strong></p><p>●&nbsp;&nbsp;&nbsp; The dose depends on the type of infection that you have, where the infection is in the body and how serious the infection is. Your doctor will decide on the dose that you need.</p><p>●&nbsp;&nbsp;&nbsp; The dose for adults is usually between 500 mg (milligrams) and 2 g (gram). You will usually receive a dose every 8 hours. However, you may receive a dose less often, if your kidneys do not work very well.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>●&nbsp;&nbsp;&nbsp; The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10 mg and 40 mg of Meroza for each kilogram (kg) that the child weighs. A dose is usually given every 8 hours. Children who weigh over 50 kg will be given an adult dose.</p><p>&nbsp;</p><p><strong>How to USE </strong><strong>MEROZA</strong></p><p>●&nbsp;&nbsp;&nbsp; Meroza will be given to you as an injection or infusion into a large vein.</p><p>●&nbsp;&nbsp;&nbsp; Your doctor or nurse will normally give Meroza to you.</p><p>●&nbsp;&nbsp;&nbsp; However, some patients, parents and carers are trained to give Meroza at home. Instructions for doing this are provided in this leaflet (in the section called &lsquo;Instructions for giving Meroza to yourself or someone else at home&rsquo;). Always use Meroza exactly as your doctor has told you. You should check with your doctor if you are not sure.</p><p>●&nbsp;&nbsp;&nbsp; Your injection should not be mixed with or added to solutions that contain other medicines.</p><p>●&nbsp;&nbsp;&nbsp; The injection may take about 5 minutes or between 15 and 30 minutes. Your doctor will tell you how to give Meroza.</p><p>●&nbsp;&nbsp;&nbsp; You should normally have your injections at the same times each day.</p><p>&nbsp;</p><p><strong>If you use more Meroza</strong> <strong>than you should </strong></p><p>If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to use Meroza</strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection.</p><p>Do not take a double dose (two injections at the same time) to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Meropenem </strong></p><p>Do not stop having Meroza until your doctor tells you to.</p><p>If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Meroza can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Severe allergic reactions </strong></p><p>If you have a severe allergic reaction, <strong>stop having Meroza</strong> <strong>and see a doctor straight away</strong>. You may need urgent medical treatment. The signs may include a sudden onset of:</p><p>●&nbsp;&nbsp;&nbsp; Severe rash, itching or hives on the skin.</p><p>●&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue or other parts of the body.</p><p>●&nbsp;&nbsp;&nbsp; Shortness of breath, wheezing or trouble breathing.</p><p>&nbsp;</p><p><strong>Damage to red blood cells (not known) </strong></p><p>The signs include:</p><p>●&nbsp;&nbsp;&nbsp; Being breathless when you do not expect it.</p><p>●&nbsp;&nbsp;&nbsp; Red or brown urine.</p><p>If you notice any of the above, <strong>see a doctor straight away</strong>.</p><p>&nbsp;</p><p><strong>Other possible side effects: </strong></p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>●&nbsp;&nbsp;&nbsp; Abdominal (stomach) pain.</p><p>●&nbsp;&nbsp;&nbsp; Feeling sick (nausea).</p><p>●&nbsp;&nbsp;&nbsp; Being sick (vomiting).</p><p>●&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>●&nbsp;&nbsp;&nbsp; Headache.</p><p>●&nbsp;&nbsp;&nbsp; Skin rash, itchy skin.</p><p>●&nbsp;&nbsp;&nbsp; Pain and inflammation.</p><p>●&nbsp;&nbsp;&nbsp; Increased numbers of platelets in your blood (shown in a blood test).</p><p>●&nbsp;&nbsp;&nbsp; Changes in blood tests, including tests that show how well your liver is working.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>●&nbsp;&nbsp;&nbsp; Changes in your blood. These include reduced numbers of platelets (which may make you bruise more easily), increased numbers of some white blood cells, decreased numbers of other white cells and increased amounts of a substance called &lsquo;bilirubin&rsquo;. Your doctor may do blood tests from time to time.</p><p>●&nbsp;&nbsp;&nbsp; Changes in blood tests, including tests that show how well your kidney is working.</p><p>●&nbsp;&nbsp;&nbsp; A tingling feeling (pins and needles).</p><p>●&nbsp;&nbsp;&nbsp; Infections of the mouth or the vagina that are caused by a fungus (thrush).</p><p>●&nbsp;&nbsp;&nbsp; Inflammation of the bowel with diarrhoea.</p><p>●&nbsp;&nbsp;&nbsp; Sore veins where Meroza is injected.</p><p>●&nbsp;&nbsp;&nbsp; Other changes in your blood. The symptoms include frequent infections, high temperature and sore throat. Your doctor may do blood tests from time to time.</p><p>●&nbsp;&nbsp;&nbsp; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains.</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>●&nbsp;&nbsp;&nbsp; Fits (convulsions).</p><p>&nbsp;</p><p><strong>Frequency not known (cannot be estimated from available data)</strong></p><p>●&nbsp;&nbsp;&nbsp; Serious hypersensitivity reactions involving fever, skin rash, and changes in the blood tests that check how the liver is working (increased levels of liver enzymes) and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes. These may be signs of a multi-organ sensitivity disorder known as DRESS syndrome.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC). By reporting side affects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Meroza after the expiry date which is stated on the carton and the vial after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution: The reconstituted solutions for intravenous injection or infusion should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous injection or infusion should not exceed one hour.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If not used immediately in-use storage times and conditions are the responsibility of the user.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze the reconstituted solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is meropenem.</p><p>Each 500 mg vial contains 500 mg anhydrous meropenem as meropenem trihydrate.</p><p>Each 1 g vial contains 1 g anhydrous meropenem as meropenem trihydrate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredient is anhydrous sodium carbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Meroza is a white to light yellow powder for solution for injection or infusion in a vial. Pack sizes of 1 or 10 vials.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer:</strong></p><p><strong>DEMO S.A.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorization Holder</strong></p><p><strong>SPIMACO</strong></p><p>Al-Qassim Pharmaceutical Plant</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                January 2021.                                      
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ميروزا يحتوي على المادة الفعالة ميروبينيم وينتمي إلى مجموعة من الأدوية وهي مضادات حيوية تعرف باسم كاربابينيم. والتى تعمل على قتل البكتيريا، التي تسبب الإصابة بالعدوى الشديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم ميروزا لعلاج ما يلي عند البالغين والأطفال الذين تتراوح أعمارهم بين 3 أشهر وما فوق:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تؤثر على الرئتين (الالتهاب الرئوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئة والشعب الهوائية عند المرضى الذين يعانون من التليف الكيسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات المسالك البولية المعقدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المعقدة في البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي يمكن التقاطها أثناء أو بعد الولادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المعقدة التى تصيب الجلد والأنسجة اللينة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية الحادة فى المخ (التهاب السحايا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام ميروزا في علاج مرضى نقص العدلات المصابين بالحمى التي يشتبه في أن تكون نتيجة لعدوى بكتيرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن استخدام ميروزا في علاج العدوى بكتيرية في الدم التي قد تحدث مع نوع من العدوى المذكورة أعلاه.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تستخدم ميروزا فى الحالات الآتية:</strong><br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت مصاباً بفرط التحسس تجاه ميروبينيم أو أي من المكونات الأخرى لميروزا (المذكورة في فقرة 6).&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت مصاباً بفرط التحسس تجاه مضادات حيوية أخرى مثل البنسيلينات أو السيفالوسبورينات أو الكاربابينيمات حيث إنك قد تكون أيضاً مصاباً بفرط التحسس تجاه ميروبينيم.</p><p><strong>المحاذير والاحتياطات</strong><br />تحدث مع طبيبك المعالج أو الصيدلي قبل استخدام ميروزا.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كانت لديك مشاكل صحية مثل مشاكل بالكبد أو الكلي.<br />&bull;&nbsp;&nbsp; &nbsp;إذا كنت قد تعرضت مسبقاً لإسهال شديد بعد تناول مضادات حيوية أخرى.<br />قد تكون نتيجة الاختبار لديك إيجابية (اختبار كومس) مما يدل على وجود أجسام مضادة التى قد تدمر خلايا الدم الحمراء لديك. طبيبك المعالج سوف يناقش معك هذا الشأن.<br />إذا كنت غير واثقاً من انطباق أى من الحالات المذكورة أعلاه عليك، تواصل مع طبيبك المعالج أو الممرضة قبل استخدام ميروزا.<br /><strong>ميروزا والأدوية الأخرى</strong><br />&bull;&nbsp;&nbsp; &nbsp;فضلاً أخبر طبيبك المعالج أو الصيدلي أو الممرضة إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى. وذلك بسبب أن ميروزا قد يؤثر على فاعلية بعض الأدوية الأخرى كما أن بعض الأدوية قد يكون لها تأثير على فاعلية ميروزا.</p><p>بشكل خاص، أخبر طبيبك المعالج أو الصيدلي أو الممرضة إذا كنت تتناول أى من الأدوية الآتية:<br />&bull;&nbsp;&nbsp; &nbsp;بروبينيسيد (يستخدم لعلاج النقرس).<br />&bull;&nbsp;&nbsp; &nbsp;حمض الفالبرويك / فالبروات الصوديوم / فالبروميد (يستخدم لعلاج الصرع). حيث لا ينبغي استخدام ميروزا لأنه قد يقلل من تأثير فالبروات الصوديوم.<br />&bull;&nbsp;&nbsp; &nbsp;عامل مضاد للتخثر عن طريق الفم (يستخدم لعلاج الجلطات الدموية أو منعها).</p><p><strong>الحمل والرضاعة</strong><br />إذا كنت حاملا أو مرضعة، تعتقدين أنك حامل أو تخططين للحمل، أطلبي المشورة من طبيبك أو الصيدلي قبل استخدام هذا الدواء. حيث إنه من الأفضل تجنب استخدام ميروبينيم خلال فترة الحمل.<br />سوف يقرر طبيبك المعالج ما إذا كان من الضروري استخدام ميروزا.<br />من الضرورى عليكِ إخبار طبيبك المعالج إذا كنتِ ترضعين طفلك طبيعياً أو ترغبين فى إرضاع طفلك طبيعياً قبل استخدام ميروبينيم. حيث إن كمية قليلة من هذا الدواء قد تمر إلى لبن الثدي. لذلك، سوف يقرر طبيبك المعالج إذا كان من الضروري استخدام ميروزا خلال فترة الرضاعة.<br /><strong>القيادة واستخدام الآلات:</strong><br />لم يتم إجراء دراسات على تأثير هذا الدواء على القيادة واستخدام الآلات.<br />ارتبط عقار ميروبينيم بالصداع والوخز أو وخز الجلد (التنميل). قد تؤثر أي من هذه الأعراض الجانبية على قدرتك على القيادة أو تشغيل الآلات.<br />.قد يسبب ميروزا حركات عضلية لا إرادية مما قد يتسبب في اهتزاز جسم الشخص بسرعة وبشكل لا يمكن السيطرة عليه (التشنجات). عادة ما يكون هذا مصحوبًا بفقدان الوعي. لا تقود السيارة أو تستخدم الآلات إذا واجهت هذا العرض الجانبي.<br /><strong>ميروزا يحتوي على الصوديوم</strong><br />ميروزا 500 ملجم: هذا الدواء يحتوي على ما يقرب من 45 ملجم مكافئ من الصوديوم (المكون الرئيسي للطبخ/ ملح الطعام) لكل جرعة من 500 ملجم وهذا يعادل 2.25٪ من الحد الأقصى الموصي به من المدخول الغذائي اليومي من الصوديوم للشخص البالغ.<br />ميروزا 1 جم: هذا الدواء يحتوي على ما يقرب من 90 ملجم مكافئ من الصوديوم (المكون الرئيسي للطبخ / ملح الطعام) لكل جرعة من 1 جم وهذا يعادل 4.50٪ من الحد الأقصى الموصي به من المدخول الغذائي اليومي من الصوديوم للشخص البالغ.<br />إذا كانت لديك حالة تتطلب منك رصد كمية الصوديوم التي تتناولها يرجى إبلاغ طبيبك المعالج أو الصيدلي او الممرضة.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قم دائما بتناول الدواء تماما كما أخبرك الطبيب المعالج أو الصيدلي او الممرضة. إذا كنت غير واثق يجب عليك التحقق من خلال الطبيب أو الصيدلي او الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام للبالغين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يعتمد تحديد الجرعة على نوعية العدوى والمكان المصاب فى الجسم ومدى شدة هذه العدوى. وسوف يقرر طبيبك المعالج الجرعة التى تحتاج إليها.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عادةً تتراوح الجرعة للبالغين ما بين 500 ملجم (مليجرام) و2 جم (جرام). سوف تتلقى عادةً جرعة كل 8 ساعات. ومع ذلك، فقد تتلقى جرعة أقل في كثير من الأحيان إذا الكليتين لديك لا تعمل بشكل جيد جداً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام للأطفال والمراهقين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تحديد الجرعة للأطفال الأكثر من 3 أشهر حتى 12 سنة من العمر باستخدام عمر ووزن الطفل. الجرعة المعتادة هي ما بين 10 ملجم و40 ملجم من ميروزا لكل كيلوجرام (كجم) من وزن الطفل. وعادةً ما يعطى جرعة كل 8 ساعات. وللأطفال الزائد وزنهم عن 50 كجم يتم إعطاؤهم جرعة البالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام ميروزا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يتم تلقى الجرعة من ميروزا عن طريق الحقن أو التسريب فى وريد كبير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يقوم الطبيب أو الممرضة بشكل طبيعى بإعطائك ميروزا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ومع ذلك، في حالة بعض المرضى يتم تدريب الآباء ومقدمى الرعاية على إعطاء ميروزا بالمنزل. وتقدم الإرشادات للقيام بذلك في هذه النشرة (في القسم المسمى &quot;تعليمات لإعطاء ميروزا لنفسك أو لشخص آخر في المنزل&quot;). قم دائماً باستخدام ميروزا تماماً كما أخبرك طبيبك المعالج. وفى حالة عدم تأكدك يجب أن تتحقق من خلال طبيبك المعالج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغى مزج أو إضافة الحقنة الخاصة بك إلى المحاليل التي تحتوي على أدوية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تستغرق الحقنة حوالي 5 دقائق أو ما بين 15 إلى 30 دقيقة. وسوف يخبرك طبيبك المعالج بكيفية إعطاء ميروزا.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ينبغى عليك تلقى الحقن الخاصة بك بشكل طبيعي في نفس الأوقات كل يوم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>في حالة استخدام ميروزا أكثر مما ينبغى</strong></p><p dir="RTL">فى حالة استخدامك لجرعة أكبر من تلك الموصوفة لك عن طريق الخطأ، تواصل مع طبيبك المعالج أو توجه إلى أقرب مستشفى فى الحال.</p><p dir="RTL"><strong>فى حالة نسيان استخدام ميروزا </strong></p><p dir="RTL">فى حالة نسيان تلقى حقنة من ميروزا، يجب عليك تلقيها فى أقرب وقت ممكن. ومع ذلك، إذا كان هذا الوقت هو وقت تلقى الحقنة التالية، تخطى الحقنة المفقودة.</p><p dir="RTL">لا تقم بمضاعفة الجرعة (بمعنى تلقى حقنتين فى نفس الوقت) لتعويض الجرعة المفقودة.</p><p dir="RTL"><strong>فى حالة التوقف عن استخدام ميروبينيم</strong></p><p dir="RTL">لا تتوقف عن تلقى ميروزا حتى يخبرك طبيبك المعالج بذلك.</p><p dir="RTL">إذا كانت لديك أية أسئلة بشأن استخدام هذا الدواء، اسأل طبيبك المعالج أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، ميروزا قد يسبب أعراضاً جانبية، وإن لم تحدث لكل من يستخدم هذا الدواء.<br /><strong>تفاعلات تحسسية حادة</strong><br />إذا كانت لديك تفاعلات تحسسية حادة، <strong>توقف عن استخدام ميروزا وتوجه إلى طبيبك المعالج فوراً.</strong> حيث قد تحتاج&nbsp;<br />إلى تدخل طبي عاجل. قد تشتمل العلامات على ظهور مفاجئ لما يلي:<br />&bull;&nbsp;&nbsp; &nbsp;طفح جلدي شديد أو حكة أو شرى على الجلد.<br />&bull;&nbsp;&nbsp; &nbsp;تورم في الوجه والشفتين واللسان أو أجزاء أخرى من الجسم.<br />&bull;&nbsp;&nbsp; &nbsp;ضيق أو صعوبة في التنفس وصوت أزيز فى الصدر.</p><p><strong>تلف خلايا الدم الحمراء (غير معروف معدل حدوثه)</strong><br />وتشمل علاماته ما يلي:<br />&bull;&nbsp;&nbsp; &nbsp;انقطاع التنفس عندما لا تتوقع ذلك.<br />&bull;&nbsp;&nbsp; &nbsp;تلون البول باللون الأحمر أو البنى.<br />إذا لاحظت أي من العلامات المذكورة أعلاه، يرجى استشارة الطبيب على الفور.</p><p><strong>أعراض جانبية أخرى محتملة الحدوث:</strong></p><p><strong>شائعة (والتي قد تصيب ما يصل الي 1 من كل 10 أشخاص)</strong><br />&bull;&nbsp;&nbsp; &nbsp;ألم في البطن (المعدة).<br />&bull;&nbsp;&nbsp; &nbsp;شعور بالإعياء (غثيان).<br />&bull;&nbsp;&nbsp; &nbsp;تقيؤ.<br />&bull;&nbsp;&nbsp; &nbsp;إسهال.<br />&bull;&nbsp;&nbsp; &nbsp;صداع.<br />&bull;&nbsp;&nbsp; &nbsp;طفح جلدى وحكة بالجلد.<br />&bull;&nbsp;&nbsp; &nbsp;ألم والتهاب.<br />&bull;&nbsp;&nbsp; &nbsp;زيادة عدد الصفائح الدموية بالدم (والتى تظهر من اختبار الدم).<br />&bull;&nbsp;&nbsp; &nbsp;تغيرات في اختبارات الدم، وتشمل الاختبارات التي توضح مدى كفاءة عمل الكبد لديك.</p><p><strong>غير شائعة (والتي قد تصيب ما يصل الي 1 من كل 100 شخص)</strong><br />&bull;&nbsp;&nbsp; &nbsp;تغيرات في الدم لديك. والتى تشمل نقص فى عدد الصفائح الدموية (والتى قد تزيد من سهولة تعرضك للكدمة)، زيادة فى أعداد بعض خلايا الدم البيضاء، نقص في أعداد بعض خلايا الدم البيضاء الأخرى وزيادة الكمية من مادة تسمى &quot;بيليروبين&quot;. لذا قد يلجأ طبيبك المعالج إلى إجراء اختبارات للدم من وقت إلى آخر.&nbsp;<br />&bull;&nbsp;&nbsp; &nbsp;تغيرات في اختبارات الدم، وتشمل الاختبارات التي توضح مدى كفاءة عمل الكلي لديك.<br />&bull;&nbsp;&nbsp; &nbsp;شعور بالوخز (الدبابيس والإبر).<br />&bull;&nbsp;&nbsp; &nbsp;التهابات في الفم أو المهبل والتي تنتج عن نوع من الفطريات (القلاع).<br />&bull;&nbsp;&nbsp; &nbsp;التهاب الأمعاء مع إسهال.<br />&bull;&nbsp;&nbsp; &nbsp;تقرح في الأوردة في مكان حقن ميروزا.<br />&bull;&nbsp;&nbsp; &nbsp;تغيرات أخرى في الدم لديك. الأعراض تشمل تكرار العدوى، ارتفاع في درجة الحرارة والتهاب الحلق. لذا قد يلجأ طبيبك المعالج إلى إجراء اختبارات للدم من وقت إلى آخر.<br />&bull;&nbsp;&nbsp; &nbsp;ظهور مفاجئ لطفح جلدي شديد أو تقرحات أو تقشير الجلد. قد تترافق هذه مع ارتفاع في درجة الحرارة وآلام في المفاصل.</p><p><strong>نادرة (والتي قد تصيب ما يصل الي 1 من كل 1000 شخص)</strong><br />&bull;&nbsp;&nbsp; &nbsp;نوبات (تشنجات).&nbsp;</p><p><strong>معدل التكرارغير معروف، (لا يمكن تقديره من البيانات المتاحة):</strong><br />&bull;&nbsp;&nbsp; &nbsp;تفاعلات فرط حساسية خطيرة تشمل حمى وطفح جلدي وتغيرات في اختبارات الدم التي تتحقق من وظائف الكبد (زيادة مستويات إنزيمات الكبد) وزيادة نوع من خلايا الدم البيضاء (فرط الحمضات) وتضخم الغدد الليمفاوية. قد تكون هذه علامات لاضطراب حساسية الأعضاء المتعددة تعرف بالتفاعل الدوائي أو الطفح الجلدي مع فرط الحمضات والأعراض الجهازية.</p><p><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا ظهرت عليك أي أعراض جانبية، قم بالتحدث مع طبيبك أو الصيدلي أو الممرضة. ويشمل ذلك أي أعراض جانبية محتملة غير المُدرجة في هذه النشرة. يمكنك أيضا الإبلاغ عن الأعراض الجانبية مباشرة عبر المركز الوطني للتيقظ والسلامة الدوائية. يمكنك من خلال الإبلاغ عن الأعراض الجانبية أن تساعد في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp; &nbsp;لا يحفظ في درجة حرارة أعلي من 30 درجة مئوية.<br />-&nbsp;&nbsp; &nbsp;يحفظ بعيداً عن متناول ونظر الأطفال.<br />-&nbsp;&nbsp; &nbsp;لا تقم باستخدام ميروزا بعد انتهاء تاريخ الصلاحية المدون على الكرتونة أو القنينة بعد كلمة &ldquo;EXP&rdquo;. تاريخ الصلاحية يشير إلى آخر يوم من الشهر المذكور على العبوة.<br />-&nbsp;&nbsp; &nbsp;بعد إعداد المحلول: يجب استخدام المحلول المعدّ للحقن أو التسريب فى الوريد فوراً. الفاصل الزمنى بين بداية إعداد المحلول والانتهاء من الحقن أو التسريب فى الوريد يجب ألّا يزيد عن ساعة واحدة.<br />-&nbsp;&nbsp; &nbsp;من وجهة نظر ميكروبيولوجية، ما لم تكن طريقة الفتح/ إعداد المحلول/ التخفيف تمنع خطر التلوث الميكروبيولوجي، يجب استخدام المنتج على الفور. في حالة عدم الاستخدام الفوري، فان أوقات وظروف التخزين اثناء الاستخدام مسؤولية المستخدم.<br />-&nbsp;&nbsp; &nbsp;لا تقم بتجميد المحلول المعدّ للحقن أو التسريب فى الوريد.<br />-&nbsp;&nbsp; &nbsp;لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدم. وسوف تساعد هذه التدابير على حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp; &nbsp;المادة الفعالة هي ميروبينيم.&nbsp;<br />تحتوي كل قنينة 500 ملجم على 500 ملجم من ميروبينيم لامائي على شكل ميروبينيم ثلاثي التميّه.<br />تحتوي كل قنينة 1 جم على 1 جم من ميروبينيم لامائي على شكل ميروبينيم ثلاثي التميّه.<br />-&nbsp;&nbsp; &nbsp;مكونات أخرى: كربونات الصوديوم اللامائي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ميروزا عبارة عن مسحوق لونه من أبيض إلى أصفر فاتح داخل قنينة معد للحلّ للحقن أو التسريب فى الوريد.<br />أحجام العبوة 1 أو 10 قنينات.<br />ليست جميع أحجام العبوات معدّة للتسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ديمو</strong><strong> </strong><strong>إس</strong><strong>.</strong><strong> إيه.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك الحقوق التسويقية</strong></p><p dir="RTL"><strong>الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يناير 2021.                                         
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Meroza 500mg powder for solution for injection or infusion 
Meroza 1000mg powder for solution for injection or infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Meroza 500 mg 

Each vial contains meropenem trihydrate equivalent to 500 mg anhydrous meropenem. 

Meroza 1 g 

Each vial contains meropenem trihydrate equivalent to 1 g anhydrous meropenem. 

Excipients: 
Each 500 mg vial contains 104 mg sodium carbonate which equates to approximately 2.0 mEq of sodium (approximately 45 mg). 
Each 1 g vial contains 208 mg sodium carbonate which equates to approximately 4.0 mEq of sodium (approximately 90 mg). 
For a full list of excipients, see section 6.1. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection or infusion 
A white to light yellow powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Meroza is indicated for the treatment of the following infections in adults and children over 3 months of age (see sections 4.4 and 5.1):</p><p>&nbsp;</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe pneumonia, including hospital and ventilator-associated pneumonia</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Broncho-pulmonary infections in cystic fibrosis</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated intra-abdominal infections</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intra- and post-partum infections</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissue infections</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial meningitis</p><p>&nbsp;</p><p>Meroza may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>&nbsp;</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The tables below provide general recommendations for dosing.</p><p>&nbsp;</p><p>The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.</p><p>&nbsp;</p><p>A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g., <em>Enterobacteriaceae, Pseudomonas aeruginosa, </em>Acinetobacter<em> </em>spp.), or very severe infections.</p><p>Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).</p><p>&nbsp;</p><p><u>Adults and adolescents </u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Dose to be administered every 8 hours</p></td></tr><tr><td style="vertical-align:top"><p>Severe pneumonia including hospital and ventilator-associated pneumonia</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>2 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Intra- and post-partum infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis</p></td><td style="vertical-align:top"><p>2 g</p></td></tr><tr><td style="vertical-align:top"><p>Management of febrile neutropenic patients</p></td><td style="vertical-align:top"><p>1 g</p></td></tr></tbody></table><p>&nbsp;</p><p>Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see section 6.2, 6.3 and 6.6).</p><p>&nbsp;</p><p>Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.</p><p>&nbsp;</p><p><em><u>Renal impairment </u></em></p><p>The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the application of these dose adjustments for a unit dose of 2 g.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Creatinine clearance (mL/min)</p></td><td style="vertical-align:top"><p>Dose (based on &ldquo;unit&rdquo; dose range of 500 mg or 1 g or 2 g, see table above)</p></td><td style="vertical-align:top"><p>Frequency</p></td></tr><tr><td style="vertical-align:top"><p>26-50</p></td><td style="vertical-align:top"><p>one-unit dose</p></td><td style="vertical-align:top"><p>every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>10-25</p></td><td style="vertical-align:top"><p>half of one-unit dose</p></td><td style="vertical-align:top"><p>every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt;10</p></td><td style="vertical-align:top"><p>half of one-unit dose</p></td><td style="vertical-align:top"><p>every 24 hours</p></td></tr></tbody></table><p>&nbsp;</p><p>Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.</p><p>&nbsp;</p><p>There are no established dose recommendations for patients receiving peritoneal dialysis.</p><p>&nbsp;</p><p><em><u>Hepatic impairment </u></em></p><p>No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).</p><p>&nbsp;</p><p><em><u>Dose in elderly patients </u></em></p><p>No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.</p><p>&nbsp;</p><p><em><u>Paediatric population </u></em></p><p><em><u>Children under 3 months of age </u></em></p><p>The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).</p><p>&nbsp;</p><p><em><u>Children from 3 months to 11 years of age and up to 50 kg body weight </u></em></p><p>The recommended dose regimens are shown in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Infection</p></td><td style="vertical-align:top"><p>Dose to be administered every 8 hours</p></td></tr><tr><td style="vertical-align:top"><p>Severe pneumonia including hospital and ventilator-associated pneumonia</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>40 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis</p></td><td style="vertical-align:top"><p>40 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Management of febrile neutropenic patients</p></td><td style="vertical-align:top"><p>20 mg/kg</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Children over 50 kg body weight</em></p><p>The adult dose should be administered.</p><p>&nbsp;</p><p>There is no experience in children with renal impairment.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Hypersensitivity to any other carbapenem antibacterial agent. 
Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or cephalosporins) 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.</p><p>&nbsp;</p><p><em><u>Enterobacteriaceae</u></em><u>, <em>Pseudomonas aeruginosa </em>and <em>Acinetobacter </em>spp. resistance</u></p><p>Resistance to penems of <em>Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter </em>spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.</p><p><u>&nbsp;</u></p><p><u>Hypersensitivity reactions</u></p><p>As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.</p><p>&nbsp;</p><p>If a severe allergic reaction occurs, the medicinal product should be discontinued, and appropriate measures taken.</p><p>&nbsp;</p><p><u>Antibiotic<em>-</em>associated colitis</u></p><p>Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for <em>Clostridium difficile</em> should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).</p><p>&nbsp;</p><p><u>Hepatic function monitoring</u></p><p>Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) (see section 4.8).</p><p>&nbsp;</p><p>Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).</p><p>&nbsp;</p><p><u>Direct antiglobulin test (Coombs test) seroconversion</u></p><p>A positive direct or indirect Coombs test may develop during treatment with meropenem.</p><p>&nbsp;</p><p><u>Concomitant use with valproic acid/sodium valproate/valpromide</u></p><p>The concomitant use of meropenem and valproic acid/sodium valproate is not recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Meroza contains sodium</u></p><p>Meroza 500 mg: This medicinal product contains approximately 45 mg of sodium per 500 mg dose, equivalent to 2.25 % of the WHO recommended maximum daily intake of 2 g sodium for an adult. &nbsp;</p><p>&nbsp;</p><p>Meroza 1.0 g: This medicinal product contains approximately 90 mg of sodium per 1.0 g dose, equivalent to 4.5 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific medicinal product interaction studies other than probenecid were conducted.</p><p>&nbsp;</p><p>Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.</p><p>&nbsp;</p><p>The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.</p><p>&nbsp;</p><p>Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).</p><p>&nbsp;</p><p><em>Oral anti-coagulants </em></p><p>Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy </u></em></p><p>Pregnancy category B</p><p>There are no or limited amount of data from the use of meropenem in pregnant women.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u><em> </em></p><p>Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3%), rash (1.4%), nausea/vomiting (1.4 %) and injection site inflammation (1.1%). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6 %) and increased hepatic enzymes (1.5-4.3 %).</p><p>&nbsp;</p><p><u>Tabulated risk of adverse reactions</u></p><p>In the table below all adverse reactions are listed by system organ class and frequency: very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table 1</strong><strong> </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class </strong></p></td><td style="vertical-align:top"><p><strong>Frequency </strong></p></td><td style="vertical-align:top"><p><strong>Event </strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>oral and vaginal candidiasis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>thrombocythaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>eosinophilia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis,</p><p>haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>angioedema, anaphylaxis (see sections 4.3 and 4.4)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>paraesthesiae</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>convulsions (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, nausea, abdominal pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>antibiotic-associated colitis (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood bilirubin increased</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS Syndrome)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood creatinine increased, blood urea increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>inflammation, pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>thrombophlebitis, pain at the injection site</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Paediatric population </u></p><p>Meropenem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p><strong>For Saudi Arabia:</strong></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999.</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.</p><p>&nbsp;</p><p>In individuals with normal renal function, rapid renal elimination will occur.</p><p>&nbsp;</p><p>Haemodialysis will remove meropenem and its metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterials for systemic use, carbapenems, ATC code: J01DH02</p><p>&nbsp;</p><p><u>Mode of action </u></p><p>Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).</p><p>&nbsp;</p><p><u>Pharmacokinetic/Pharmacodynamic (PK/PD) relationship </u></p><p>Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC (T&gt;MIC) has been shown to best correlate with efficacy. In preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40 % of the dosing interval. This target has not been established clinically.</p><p>&nbsp;</p><p><u>Mechanism of resistance </u></p><p>Bacterial resistance to meropenem may result from: (1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) (2) reduced affinity of the target PBPs (3) increased expression of efflux pump components, and (4) production of beta-lactamases that can hydrolyse carbapenems.</p><p>&nbsp;</p><p>Localised clusters of infections due to carbapenem-resistant bacteria have been reported in the European Union.</p><p>&nbsp;</p><p>There is no target-based cross-resistance between meropenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes. However, bacteria may exhibit resistance to more than one class of antibacterials agents when the mechanism involved include impermeability and/or an efflux pump(s).</p><p>&nbsp;</p><p><u>Breakpoints </u></p><p>European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for MIC testing are presented below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>EUCAST clinical MIC breakpoints for meropenem (2013-02-11, v 3.1)</p></td></tr><tr><td style="vertical-align:top"><p>Organism</p></td><td style="vertical-align:top"><p>Susceptible (S) (mg/L)</p></td><td style="vertical-align:top"><p>Resistant (R) (mg/L)</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae </em></p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas </em>spp.</p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter </em>spp.</p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>groups A, B, C, G</p></td><td style="vertical-align:top"><p>note 6</p></td><td style="vertical-align:top"><p>note 6</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae<sup>1</sup></em></p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Viridans </em>group<em> streptococci<sup>2</sup></em></p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt;2</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus </em>spp.</p></td><td style="vertical-align:top"><p>--</p></td><td style="vertical-align:top"><p>--</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus<sup> </sup></em>spp.</p></td><td style="vertical-align:top"><p>note 3</p></td><td style="vertical-align:top"><p>note 3</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae<sup>1, 2 </sup></em>and <em>Moraxella catarrhalis<sup>2</sup> </em></p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis<sup>2,4</sup></em></p></td><td style="vertical-align:top"><p>&le;0.25</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p>Gram-positive anaerobes except <em>Clostridium difficile</em></p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p>Gram-negative anaerobes</p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top"><p><em>Listeria monocytogenes</em></p></td><td style="vertical-align:top"><p>&le; 0.25</p></td><td style="vertical-align:top"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>5</sup></p></td><td style="vertical-align:top"><p>&le;2</p></td><td style="vertical-align:top"><p>&gt; 8</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>1 </sup>Meropenem breakpoints for <em>Streptococcus pneumoniae </em>and <em>Haemophilus influenzae </em>in meningitis are 0.25 mg/L (Susceptible) and 1 mg/L (Resistant).</p><p><sup>2</sup> Isolates with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC values above the current resistant breakpoint they should be reported resistant.</p><p><sup>3</sup> Susceptibility of <em>staphylococci</em> to carbapenems is inferred from the cefoxitin susceptibility.</p><p><sup>4</sup> Breakpoints relate to meningitis only.</p><p><sup>5</sup> Non-species related breakpoints have been determined using PK/PD data and are independent of MIC distributions of specific species. They are for use only for organisms that do not have specific breakpoints. Non-species related breakpoints are based on the following doses: EUCAST breakpoints apply to meropenem 1000 mg x 3 daily administered intravenously over 30 minutes as the lowest dose. 2 g x 3 daily was taken into consideration for severe infections and in setting the I/R breakpoint.</p><p><sup>6</sup> The beta-lactam susceptibility of <em>streptococcus</em> groups A, B, C and G is inferred from the penicillin susceptibility.</p><p><em>-- </em>= Susceptibility testing not recommended as the species is a poor target for therapy with the medicinal product. Isolates may be reported as R without prior testing.</p><p>&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><p>The following table of pathogens listed is derived from clinical experience and therapeutic guidelines.</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Commonly susceptible species</u></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecalis<sup>$ </sup></em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>(methicillin-susceptible)<sup>&pound; </sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>species (methicillin-susceptible) including <em>Staphylococcus epidermidis </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus agalactiae </em>(Group B)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus milleri </em>group <em>(S. anginosus, S. constellatus, and S. intermedius) </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes </em>(Group A)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Citrobacter freudii </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Citrobacter koseri </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacter aerogenes </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacter cloacae </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella oxytoca </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella pneumoniae </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Morganella morganii </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus mirabilis </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus vulgaris </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Serratia marcescens </em></p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Gram-positive anaerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Clostridium perfringens </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Peptoniphilus asaccharolyticus </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Peptostreptococcus </em>species <em>(including P. micros, P anaerobius, P. magnus) </em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Gram-negative anaerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacteroides caccae </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacteroides fragilis </em>group</p></td></tr><tr><td style="vertical-align:top"><p><em>Prevotella bivia </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Prevotella disiens </em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Species for which acquired resistance may be a problem</u></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecium</em><sup>$&dagger; </sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter </em>species</p></td></tr><tr><td style="vertical-align:top"><p><em>Burkholderia cepacia </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa </em></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Inherently resistant organisms</u></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Stenotrophomonas maltophilia </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Legionella </em>species</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><u>Other micro-organisms </u></p></td></tr><tr><td style="vertical-align:top"><p><em>Chlamydophila pneumoniae </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Chlamydophila psittaci </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Coxiella burnetii </em></p></td></tr><tr><td style="vertical-align:top"><p><em>Mycoplasma pneumoniae </em></p></td></tr></tbody></table><p>&nbsp;</p><p><sup>$</sup>Species that show natural intermediate susceptibility</p><p><sup>&pound;</sup>All methicillin-resistant staphylococci are resistant to meropenem</p><p><sup>&dagger;</sup>Resistance rate &ge; 50% in one or more EU countries</p><p>&nbsp;</p><p>Glanders and melioidosis: Use of meropenem in humans is based on <em>in vitro B.mallei</em> and <em>B. pseudomallei</em> susceptibility data and on limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of glanders and melioidosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects the mean plasma half-life is approximately 1 hour; the mean volume of distribution is approximately 0.25 l/kg (11-27 l) and the mean clearance is 287 ml/min at 250 mg falling to 205 ml/min at 2 g. Doses of 500, 1000 and 2000 mg doses infused over 30 minutes give mean Cmax values of approximately 23, 49 and 115 &mu;g/ml respectively, corresponding AUC values were 39.3, 62.3 and 153 &mu;g.h/ml. After infusion over 5 minutes Cmax values are 52 and 112 &mu;g/ml after 500 and 1000 mg doses respectively. When multiple doses are administered 8-hourly to subjects with normal renal function, accumulation of meropenem does not occur.</p><p>&nbsp;</p><p>A study of 12 patients administered meropenem 1000 mg 8 hourly post-surgically for intra-abdominal infections showed a comparable Cmax and half-life to normal subjects but a greater volume of distribution 27 l.</p><p>&nbsp;</p><p><u>Distribution </u></p><p>The average plasma protein binding of meropenem was approximately 2 % and was independent of concentration. After rapid administration (5 minutes or less) the pharmacokinetics are biexponential but this is much less evident after 30 minutes infusion. Meropenem has been shown to penetrate well into several body fluids and tissues: including lung, bronchial secretions, bile, cerebrospinal fluid, gynaecological tissues, skin, fascia, muscle, and peritoneal exudates.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Meropenem is metabolised by hydrolysis of the beta-lactam ring generating a microbiologically inactive metabolite. In vitro meropenem shows reduced susceptibility to hydrolysis by human dehydropeptidase-I (DHP-I) compared to imipenem and there is no requirement to co-administer a DHP-I inhibitor.</p><p>&nbsp;</p><p><u>Elimination </u></p><p>Meropenem is primarily excreted unchanged by the kidneys; approximately 70 % (50 &ndash;75 %) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Faecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.</p><p>&nbsp;</p><p><u>Renal insufficiency </u></p><p>&nbsp;</p><p>Renal impairment results in higher plasma AUC and longer half-life for meropenem. There were AUC increases of 2.4-fold in patients with moderate impairment (CrCL 33-74 ml/min), 5-fold in severe impairment (CrCL 4-23 ml/min) and 10 fold in haemodialysis patients (CrCL &lt;2 ml/min) when compared to healthy subjects (CrCL &gt;80 ml/min). The AUC of the microbiologically inactive ring opened metabolite was also considerably increased in patients with renal impairment. Dose adjustment is recommended for patients with moderate and severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>Meropenem is cleared by haemodialysis with clearance during haemodialysis being approximately 4 times higher than in anuric patients.</p><p>&nbsp;</p><p><u>Hepatic insufficiency </u></p><p>A study in patients with alcoholic cirrhosis shows no effect of liver disease on the pharmacokinetics of meropenem after repeated doses.</p><p>&nbsp;</p><p><u>Adult patients </u></p><p>Pharmacokinetic studies performed in patients have not shown significant pharmacokinetic differences versus healthy subjects with equivalent renal function. A population model developed from data in 79 patients with intra-abdominal infection or pneumonia, showed a dependence of the central volume on weight and the clearance on creatinine clearance and age.</p><p>&nbsp;</p><p><u>Paediatric population</u><u> </u></p><p>The pharmacokinetics in infants and children with infection at doses of 10, 20 and 40 mg/kg showed Cmax values approximating to those in adults following 500, 1000 and 2000 mg doses, respectively. Comparison showed consistent pharmacokinetics between the doses and half-lives similar to those observed in adults in all but the youngest subjects (&lt;6 months t1/2 1.6 hours). The mean meropenem clearance values were 5.8 ml/min/kg (6-12 years), 6.2 ml/min/kg (2-5 years), 5.3 ml/min/kg (6-23 months) and 4.3 ml/min/kg (2-5 months). Approximately 60 % of the dose is excreted in urine over 12 hours as meropenem with a further 12 % as metabolite. Meropenem concentrations in the CSF of children with meningitis are approximately 20 % of concurrent plasma levels although there is significant inter-individual variability.</p><p>&nbsp;</p><p>The pharmacokinetics of meropenem in neonates requiring anti-infective treatment showed greater clearance in neonates with higher chronological or gestational age with an overall average half-life of 2.9 hours. Monte Carlo simulation based on a population PK model showed that a dose regimen of 20 mg/kg 8 hourly achieved 60 %T&gt;MIC for <em>P. aeruginosa </em>in 95 % of pre-term and 91 % of full-term neonates.</p><p>&nbsp;</p><p><u>Elderly </u></p><p>Pharmacokinetic studies in healthy elderly subjects (65-80 years) have shown a reduction in plasma clearance, which correlated with age-associated reduction in creatinine clearance, and a smaller reduction in non-renal clearance. No dose adjustment is required in elderly patients, except in cases of moderate to severe renal impairment (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies indicate that meropenem is well tolerated by the kidney. Histological evidence of renal tubular damage was seen in mice and dogs only at doses of 2000 mg/kg and above after a single administration and above and in monkeys at 500 mg/kg in a 7-day study.</p><p>&nbsp;</p><p>Meropenem is generally well tolerated by the central nervous system. Effects were seen in acute toxicity studies in rodent at doses exceeding 1000 mg/kg.</p><p>&nbsp;</p><p>The IV LD<sub>50</sub> of meropenem in rodents is greater that 2000 mg/kg.</p><p>&nbsp;</p><p>In repeat dose studies of up to 6 months duration only minor effects were seen including a decrease in red cell parameters in dogs.</p><p>&nbsp;</p><p>There was no evidence of mutagenic potential in a conventional test battery and no evidence of reproductive toxicity including teratogenic potential in studies in rats up to 750 mg/kg and in monkeys up to 360 mg/kg.</p><p>&nbsp;</p><p>There was no evidence of increased sensitivity to meropenem in juveniles compared to adult animals. The intravenous formulation was well tolerated in animal studies.</p><p>&nbsp;</p><p>The sole metabolite of meropenem had a similar profile of toxicity in animal studies.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium carbonate, anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those&nbsp;<br />mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened: 48 months.

After reconstitution: 
The reconstituted solutions for intravenous injection or infusion should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous injection or infusion should not exceed one hour. 

From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.
If not used immediately in-use storage times and conditions are the responsibility of the user.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.&nbsp;<br />&nbsp;<br />&nbsp;<br />Do not freeze the reconstituted solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Meroza 500mg</p><p>&nbsp;</p><p>674 mg powder in a 20 ml type I colourless glass vial with butyl rubber (type I) closures and sealed with aluminium caps.</p><p>&nbsp;</p><p>Meroza 1000mg</p><p>&nbsp;</p><p>1348 mg powder in a 30 ml type I colourless glass vials with butyl rubber (type I) closures and sealed with aluminium caps.</p><p>&nbsp;</p><p>The medicinal product is supplied in pack sizes of 1 or 10 vials.</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Injection </u></p><p>Meropenem to be used for bolus intravenous injection should be constituted with sterile water for injection to a final concentration of 50 mg/mL.</p><p>&nbsp;</p><p><em>How to prepare this medicine </em></p><p>1. Wash your hands and dry them very well. Prepare a clean working area.</p><p>2. Remove the Meroza bottle (vial) from the packaging. Check the vial and the expiry date. Check that the vial is intact and has not been damaged.</p><p>3. Remove the coloured cap and clean the grey rubber stopper with an alcohol wipe. Allow the rubber stopper to dry.</p><p>4. Connect a new sterile needle to a new sterile syringe, without touching the ends.</p><p>5. Draw up the recommended amount of sterile &lsquo;Water for Injections&rsquo; into the syringe. The amount of liquid that you need is shown in the table below:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose of Meroza</p></td><td style="vertical-align:top"><p>Amount of &lsquo;Water for Injections&rsquo; needed for dilution</p></td></tr><tr><td style="vertical-align:top"><p>500 mg (milligrams)</p></td><td style="vertical-align:top"><p>10 mL (milliliters)</p></td></tr><tr><td style="vertical-align:top"><p>1 g (gram)</p></td><td style="vertical-align:top"><p>20 mL</p></td></tr><tr><td style="vertical-align:top"><p>1.5 g</p></td><td style="vertical-align:top"><p>30 mL</p></td></tr><tr><td style="vertical-align:top"><p>2 g</p></td><td style="vertical-align:top"><p>40 mL</p></td></tr></tbody></table><p>Please note: If your prescribed dose of Meroza is more than 1 g, you will need to use more than 1 vial of Meroza. You can then draw the liquid in the vials into the one syringe.</p><p>&nbsp;</p><p>6. Put the needle of the syringe through the centre of the grey rubber stopper and inject the recommended amount of &lsquo;Water for Injections&rsquo; into the vial or vials of Meroza.</p><p>7. Remove the needle from the vial and shake the vial well for about 5 seconds, or until all the powder has dissolved. Clean the grey rubber stopper once more with a new alcohol wipe and allow the rubber stopper to dry.</p><p>8. With the plunger of the syringe pushed fully into the syringe, put the needle back through the grey rubber stopper. You must then hold both the syringe and the vial and turn the vial upside down.</p><p>9. Keeping the end of the needle in the liquid, pull back the plunger and draw all the liquid in the vial into the syringe.</p><p>10. Remove the needle and syringe from the vial and throw the empty vial away in a safe place.</p><p>11. Hold the syringe upright, with the needle pointing upwards. Tap the syringe so that any bubbles in the liquid rise to the top of the syringe.</p><p>12. Remove any air in the syringe by gently pushing the plunger until all the air has gone.</p><p>13. If you are using Meroza at home, dispose of any needles and infusion lines that you have used in an appropriate way. If your doctor decides to stop your treatment, dispose of any unused Meroza in an appropriate way. &nbsp;</p><p>&nbsp;</p><p><u>Infusion </u></p><p>For intravenous infusion meropenem vials may be directly constituted with 0.9 % sodium chloride or 5% glucose solutions for infusion to a final concentration of 1 to 20 mg/mL.</p><p>For storage conditions of the reconstituted medicinal product, see section 6.3. &nbsp;</p><p>&nbsp;</p><p>Each vial is for single use only.</p><p>&nbsp;</p><p>Standard aseptic techniques should be used for solution preparation and administration.</p><p>&nbsp;</p><p>The solution should be shaken before use.</p><p>The solutions should be inspected visually for particles prior to administration. Only clear pale-yellow solution, free from visible particles should be used.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
DEMO S.A.

Marketing Authorization Holder
SPIMACO
Al-Qassim Pharmaceutical Plant
Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>